Duyuru • Jun 30
HitGen Inc. to Report First Half, 2026 Results on Aug 27, 2026 HitGen Inc. announced that they will report first half, 2026 results on Aug 27, 2026 New Risk • Jun 28
New minor risk - Dividend sustainability The dividend is not well covered by cash flows. Cash payout ratio: 97% Dividend yield: 0.4% This is considered a minor risk. Dividends are ultimately paid out of the company's available cash reserves. Companies that pay out too much of their cash flow are at risk of having to reduce or cut their dividend in future. If cash flow growth slows or cash flows fall, then there may not be enough cash reserves to maintain the same dividend. Or in extreme cases, companies may opt to take on debt to maintain the dividend. This risk is mitigated by the fact the dividend is covered by earnings, however, cash flows are generally more important. For dividend paying companies, any reduction in the dividend can significantly impact the share price. This is currently the only risk that has been identified for the company. Declared Dividend • Jun 15
Dividend increased to CN¥0.13 Dividend of CN¥0.13 is 117% higher than last year. Ex-date: 18th June 2026 Payment date: 18th June 2026 Dividend yield will be 0.5%, which is lower than the industry average of 1.4%. Sustainability & Growth Dividend is well covered by both earnings (22% earnings payout ratio) and cash flows (30% cash payout ratio). The dividend has decreased over the past 66 years, indicating a lack of growth and stability in payments. EPS is expected to grow by 79% over the next 3 years, which should provide support to the dividend and adequate earnings cover. New Risk • May 28
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Chinese stocks, typically moving 8.3% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. This is currently the only risk that has been identified for the company. Board Change • May 20
Less than half of directors are independent Following the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 6 non-independent directors. Independent Director Xue Junfu was the last independent director to join the board, commencing their role in 2022. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Duyuru • Apr 29
HitGen Inc., Annual General Meeting, May 29, 2026 HitGen Inc., Annual General Meeting, May 29, 2026, at 14:00 China Standard Time. Location: 2F, Building C2, No. 18, Huigu Dongyi Road, Shuangliu District, Chengdu, Sichuan China Duyuru • Mar 30
HitGen Inc. to Report Q1, 2026 Results on Apr 29, 2026 HitGen Inc. announced that they will report Q1, 2026 results on Apr 29, 2026 Duyuru • Dec 26
HitGen Inc. to Report Fiscal Year 2025 Results on Apr 29, 2026 HitGen Inc. announced that they will report fiscal year 2025 results on Apr 29, 2026 Duyuru • Sep 30
HitGen Inc. to Report Q3, 2025 Results on Oct 30, 2025 HitGen Inc. announced that they will report Q3, 2025 results on Oct 30, 2025 Duyuru • Aug 27
HitGen Inc. Introduces OpenDEL™ 5.0 HitGen Inc. is raising the bar with the introduction of OpenDEL™ 5.0 - featuring a total of 4 billion diverse compounds designed to tackle challenging biological targets. OpenDEL™ 5.,0 comes in a convenient kit format that is accessible to scientists in industry and academia alike. Key Improvements: Expanded Chemical Diversity: 4 billion Compounds; Increased Library Size: Now with 25% more compounds, OpenDEL™ 5.'0 offers 3.8 billion small molecules compounds and 200 million peptide compounds to further expand chemical space for targeting protein-protein-interactions (PPI). Encompassing Library Design: 59 distinct libraries provide a broad range of chemistries to address different types of targets and discovery challenges; Optional Macrocycle Library: Unlocking Challenging Targets; A dedicated macrocycle library: Available as an add-on, featuring 4-10 amino acids in the ring. Comes with a linear peptide control library; Dual-Kit Flexibility: Choose between OpenDEL™-Small Molecules or OpenDEL™-Macrocycle - or combine both for maximum coverage; Streamlined Workflow & Faster Access; Redesigned protocols: Intuitive visual guides simplify key steps, reducing onboarding time; Expedited delivery: Next-day shipping available to minimize wait time. Duyuru • Jun 30
HitGen Inc. to Report First Half, 2025 Results on Aug 28, 2025 HitGen Inc. announced that they will report first half, 2025 results on Aug 28, 2025 Duyuru • Apr 26
HitGen Inc., Annual General Meeting, May 23, 2025 HitGen Inc., Annual General Meeting, May 23, 2025, at 14:30 China Standard Time. Location: 2F, Building C2, No. 18, Huigu East 1st Road, Shuangliu District, Chengdu, Sichuan China Duyuru • Mar 28
HitGen Inc. to Report Q1, 2025 Results on Apr 26, 2025 HitGen Inc. announced that they will report Q1, 2025 results on Apr 26, 2025 Duyuru • Dec 27
HitGen Inc. to Report Fiscal Year 2024 Results on Apr 26, 2025 HitGen Inc. announced that they will report fiscal year 2024 results on Apr 26, 2025 New Risk • Nov 13
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Chinese stocks, typically moving 10% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. This is currently the only risk that has been identified for the company. Reported Earnings • Oct 26
Third quarter 2024 earnings released: EPS: CN¥0.18 (vs CN¥0.031 in 3Q 2023) Third quarter 2024 results: EPS: CN¥0.18 (up from CN¥0.031 in 3Q 2023). Revenue: CN¥103.5m (up 15% from 3Q 2023). Net income: CN¥19.9m (up 60% from 3Q 2023). Profit margin: 19% (up from 14% in 3Q 2023). The increase in margin was driven by higher revenue. Revenue is forecast to grow 20% p.a. on average during the next 3 years, compared to a 13% growth forecast for the Life Sciences industry in China. Buy Or Sell Opportunity • Oct 22
Now 23% overvalued after recent price rise Over the last 90 days, the stock has risen 28% to CN¥12.32. The fair value is estimated to be CN¥10.00, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 9.1% over the last 3 years. Earnings per share has declined by 19%. Revenue is forecast to grow by 36% in 2 years. Earnings are forecast to grow by 56% in the next 2 years. New Risk • Sep 30
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Chinese stocks, typically moving 6.9% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. This is currently the only risk that has been identified for the company. Duyuru • Sep 30
HitGen Inc. to Report Q3, 2024 Results on Oct 26, 2024 HitGen Inc. announced that they will report Q3, 2024 results on Oct 26, 2024 Buy Or Sell Opportunity • Jul 31
Now 20% overvalued Over the last 90 days, the stock has fallen 24% to CN¥10.30. The fair value is estimated to be CN¥8.58, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 9.1% over the last 3 years. Earnings per share has declined by 23%. Revenue is forecast to grow by 30% in 2 years. Earnings are forecast to grow by 1.1% in the next 2 years. Buy Or Sell Opportunity • Jul 11
Now 25% overvalued Over the last 90 days, the stock has fallen 13% to CN¥10.84. The fair value is estimated to be CN¥8.69, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 9.1% over the last 3 years. Earnings per share has declined by 23%. Revenue is forecast to grow by 30% in 2 years. Earnings are forecast to grow by 1.1% in the next 2 years. Duyuru • Jun 29
HitGen Inc. to Report First Half, 2024 Results on Aug 29, 2024 HitGen Inc. announced that they will report first half, 2024 results on Aug 29, 2024 Duyuru • Apr 26
HitGen Inc., Annual General Meeting, May 22, 2024 HitGen Inc., Annual General Meeting, May 22, 2024, at 14:30 China Standard Time. Location: 6F, No. 1166, Jiannan Avenue South Section, Shuangliu District, Chengdu, Sichuan China Reported Earnings • Apr 25
First quarter 2024 earnings released: EPS: CN¥0.03 (vs CN¥0.02 loss in 1Q 2023) First quarter 2024 results: EPS: CN¥0.03 (up from CN¥0.02 loss in 1Q 2023). Revenue: CN¥107.4m (up 54% from 1Q 2023). Net income: CN¥13.9m (up CN¥23.3m from 1Q 2023). Profit margin: 13% (up from net loss in 1Q 2023). The move to profitability was driven by higher revenue. Revenue is forecast to grow 29% p.a. on average during the next 3 years, compared to a 13% growth forecast for the Life Sciences industry in China. Duyuru • Mar 29
HitGen Inc. to Report Q1, 2024 Results on Apr 25, 2024 HitGen Inc. announced that they will report Q1, 2024 results on Apr 25, 2024 Buy Or Sell Opportunity • Mar 21
Now 23% undervalued The stock has been flat over the last 90 days, currently trading at CN¥14.98. The fair value is estimated to be CN¥19.40, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 9.2% over the last 3 years. Earnings per share has declined by 32%. Revenue is forecast to grow by 36% in 2 years. Earnings are forecast to grow by 37% in the next 2 years. Reported Earnings • Feb 25
Full year 2023 earnings released: EPS: CN¥0.11 (vs CN¥0.06 in FY 2022) Full year 2023 results: EPS: CN¥0.11 (up from CN¥0.06 in FY 2022). Revenue: CN¥371.7m (up 13% from FY 2022). Net income: CN¥43.9m (up 74% from FY 2022). Profit margin: 12% (up from 7.7% in FY 2022). The increase in margin was driven by higher revenue. Revenue is forecast to grow 29% p.a. on average during the next 3 years, compared to a 18% growth forecast for the Life Sciences industry in China. Reported Earnings • Nov 01
Third quarter 2023 earnings released Third quarter 2023 results: Revenue: CN¥90.1m (up 13% from 3Q 2022). Net income: CN¥12.5m (down 29% from 3Q 2022). Profit margin: 14% (down from 22% in 3Q 2022). Revenue is forecast to grow 28% p.a. on average during the next 3 years, compared to a 21% growth forecast for the Life Sciences industry in China. New Risk • Oct 30
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Chinese stocks, typically moving 6.3% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (6.3% average weekly change). Large one-off items impacting financial results. Reported Earnings • Aug 24
Second quarter 2023 earnings released: EPS: CN¥0.022 (vs CN¥0 in 2Q 2022) Second quarter 2023 results: EPS: CN¥0.022 (up from CN¥0 in 2Q 2022). Revenue: CN¥86.1m (up 30% from 2Q 2022). Net income: CN¥15.2m (up CN¥15.2m from 2Q 2022). Profit margin: 18% (up from 0% in 2Q 2022). Revenue is forecast to grow 29% p.a. on average during the next 3 years, compared to a 19% growth forecast for the Life Sciences industry in China. Duyuru • Jun 28
HitGen Inc. to Report Q2, 2023 Results on Aug 23, 2023 HitGen Inc. announced that they will report Q2, 2023 results on Aug 23, 2023 Duyuru • Jun 27
HitGen Inc. Launches A Newly Upgraded Version of OpenDEL™, A Self-Service Screening Kit, to Facilitate Innovative Drug Discovery Research HitGen Inc. has recently launched a newly upgraded version of its OpenDEL™? product, a self-service screening kit for novel molecules. It contains 65% more DEL libraries than the previous version, and with over 3 billion compounds. The 2-cycle and 3-cycle libraries in the kit are designed with excellent drug-like properties. The upgraded OpenDEL™? provides more diverse options with more flexible packages and service models to meet more differentiated user needs. OpenDEL™? is a self-service DNA-encoded library (DEL) kit, which enables users to explore DEL selection campaigns without revealing the target identity. Under the guidance of the manual and operating instructions, users can utilize OpenDEL™? to conduct affinity screening experiments against protein targets in their own laboratories. HitGen can provide upstream and downstream technical support. OpenDEL™? are a fully-open, transparent, small molecule screening kit, featuring complete disclosure of information for molecular structures, building blocks, scaffolds and compound encoding sequences. The users do not need to pay structure disclosure fees, nor compound IP license fees. OpenDEL™? can be widely applied in multiple areas, including drug discovery and AI-ML research. In the drug discovery scenarios, the complete information disclosure of OpenDEL™? can enable efficient and convenient discovery of novel hits and lead compounds. In the AI-ML scenarios, OpenDEL™? can provide a large number of high-quality screening data to facilitate the AI/ML predictive model building, algorithm development and validation, as well as other frontier explorations, thus promoting the AI-driven drug development. Since its release, OpenDEL™? has been widely used and highly recognized by many users from more than 10 countries, including biopharmaceutical companies, AI technology companies, academic institutions and colleges. Board Change • Jun 15
Less than half of directors are independent No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 6 experienced directors. No highly experienced directors. 2 independent directors (3 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment. 
